PMID- 19604651
OWN - NLM
STAT- MEDLINE
DCOM- 20090910
LR  - 20090821
IS  - 1879-355X (Electronic)
IS  - 0360-3016 (Linking)
VI  - 75
IP  - 1
DP  - 2009 Sep 1
TI  - Response surface methodology: an extensive potential to optimize in vivo 
      photodynamic therapy conditions.
PG  - 244-52
LID - 10.1016/j.ijrobp.2009.04.004 [doi]
AB  - PURPOSE: Photodynamic therapy (PDT) is based on the interaction of a 
      photosensitizing (PS) agent, light, and oxygen. Few new PS agents are being 
      developed to the in vivo stage, partly because of the difficulty in finding the 
      right treatment conditions. Response surface methodology, an empirical modeling 
      approach based on data resulting from a set of designed experiments, was 
      suggested as a rational solution with which to select in vivo PDT conditions by 
      using a new peptide-conjugated PS targeting agent, neuropilin-1. METHODS AND 
      MATERIALS: A Doehlert experimental design was selected to model effects and 
      interactions of the PS dose, fluence, and fluence rate on the growth of U87 human 
      malignant glioma cell xenografts in nude mice, using a fixed drug-light interval. 
      All experimental results were computed by Nemrod-W software and Matlab. RESULTS: 
      Intrinsic diameter growth rate, a tumor growth parameter independent of the 
      initial volume of the tumor, was selected as the response variable and was 
      compared to tumor growth delay and relative tumor volumes. With only 13 
      experimental conditions tested, an optimal PDT condition was selected (PS agent 
      dose, 2.80 mg/kg; fluence, 120 J/cm(2); fluence rate, 85 mW/cm(2)). Treatment of 
      glioma-bearing mice with the peptide-conjugated PS agent, followed by the 
      optimized PDT condition showed a statistically significant improvement in 
      delaying tumor growth compared with animals who received the PDT with the 
      nonconjugated PS agent. CONCLUSIONS: Response surface methodology appears to be a 
      useful experimental approach for rapid testing of different treatment conditions 
      and determination of optimal values of PDT factors for any PS agent.
FAU - Tirand, Loraine
AU  - Tirand L
AD  - Centre de Recherche en Automatique de Nancy, Nancy-University, CNRS, Centre 
      Alexis Vautrin, Vandoeuvre-les-Nancy, France.
FAU - Bastogne, Thierry
AU  - Bastogne T
FAU - Bechet, Denise
AU  - Bechet D
FAU - Linder, Michel
AU  - Linder M
FAU - Thomas, Noemie
AU  - Thomas N
FAU - Frochot, Celine
AU  - Frochot C
FAU - Guillemin, Francois
AU  - Guillemin F
FAU - Barberi-Heyob, Muriel
AU  - Barberi-Heyob M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090713
PL  - United States
TA  - Int J Radiat Oncol Biol Phys
JT  - International journal of radiation oncology, biology, physics
JID - 7603616
RN  - 0 (Oligopeptides)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (TPC-Ahx-ATWLPPR)
RN  - 144713-63-3 (Neuropilin-1)
SB  - IM
MH  - Algorithms
MH  - Animals
MH  - Cell Line, Tumor
MH  - Female
MH  - Glioma/drug therapy/metabolism/pathology
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - *Models, Statistical
MH  - *Neuropilin-1
MH  - Oligopeptides/*therapeutic use
MH  - Photochemotherapy/*methods
MH  - Photosensitizing Agents/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Time Factors
MH  - Tumor Burden
MH  - Xenograft Model Antitumor Assays/methods
EDAT- 2009/07/17 09:00
MHDA- 2009/09/11 06:00
CRDT- 2009/07/17 09:00
PHST- 2008/11/07 00:00 [received]
PHST- 2009/03/13 00:00 [revised]
PHST- 2009/04/06 00:00 [accepted]
PHST- 2009/07/17 09:00 [entrez]
PHST- 2009/07/17 09:00 [pubmed]
PHST- 2009/09/11 06:00 [medline]
AID - S0360-3016(09)00521-5 [pii]
AID - 10.1016/j.ijrobp.2009.04.004 [doi]
PST - ppublish
SO  - Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):244-52. doi: 
      10.1016/j.ijrobp.2009.04.004. Epub 2009 Jul 13.